Related Experiment Video
Updated: Feb 16, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis
ShuYan Liu1, Xiao Li1, ZhaoMin Lin2
1Shandong Provincial Key Laboratory of Animal Cells and Developmental Biology, School of Life Science, Shandong University, Jinan 250100, China.
Abstract:
Annexin A7 (ANXA7) is a suppressor of tumorigenesis and metastasis in prostate cancer. Activated ANXA7 GTPase promotes prostate cancer cell apoptosis. However, the role and underlying mechanism of ANXA7 GTPase in prostate cancer metastasis have not been established. RKIP is a metastatic suppressor and downregulated in prostate cancer metastases. The binding of RKIP and its target proteins could inhibit the activation of its interactive partners. However, the effect of RKIP on ANXA7 GTPase activation is not clear. Here, we report that activation of ANXA7 GTPase by a small molecule SEC ((S)-ethyl 1-(3-(4-chlorophenoxy)-2-hydroxypropyl)-3- (4-methoxyphenyl)-1H-pyrazole-5-carboxylate) effectively inhibited prostate cancer metastasis. Mechanistically, activated ANXA7 promoted AMPK phosphorylation, leading to decreased mTORC1 activity, suppressed STAT3 nuclear translocation, and downregulation of pro-metastatic genes, including CCL2, APLN, and IL6ST. Conversely, RKIP interacted with ANXA7 and impaired activation of ANXA7 GTPase by SEC and its downstream signaling pathway. Notably, SEC treatment suppressed metastasis of prostate cancer cells in in vivo orthotopic analysis. Together, our findings provide a novel insight into how metastasis of prostate cancer with low RKIP expression is suppressed by SEC-induced activation of ANXA7 GTPase via the AMPK/mTORC1/STAT3 signaling pathway.
Insights
A novel small molecule SEC activates Annexin A7 GTPase (ANXA7), inhibiting prostate cancer metastasis. This occurs via the AMPK/mTORC1/STAT3 pathway, even when RKIP is low.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Annexin A7 (ANXA7) functions as a tumor suppressor in prostate cancer, with its activated GTPase promoting apoptosis.
- The metastatic suppressor RKIP is downregulated in prostate cancer metastases, and its interaction with proteins can inhibit their activation.
- The precise role and mechanism of ANXA7 GTPase in prostate cancer metastasis remain unclear.
Purpose of the Study:
- To investigate the mechanism by which ANXA7 GTPase influences prostate cancer metastasis.
- To determine the effect of RKIP on ANXA7 GTPase activation.
- To evaluate the therapeutic potential of activating ANXA7 GTPase using a small molecule SEC.
Main Methods:
- Activation of ANXA7 GTPase using the small molecule SEC.
- Analysis of downstream signaling pathways including AMPK, mTORC1, and STAT3.
- Assessment of pro-metastatic gene expression (CCL2, APLN, IL6ST).
- Investigation of RKIP interaction with ANXA7.
- In vivo orthotopic analysis of prostate cancer metastasis.
Main Results:
- SEC-induced ANXA7 GTPase activation significantly inhibited prostate cancer metastasis.
- Activated ANXA7 promoted AMPK phosphorylation, leading to reduced mTORC1 activity and suppressed STAT3 nuclear translocation.
- RKIP was found to interact with ANXA7, impairing SEC-mediated activation and downstream signaling.
- SEC treatment suppressed prostate cancer cell metastasis in vivo.
- Downregulation of pro-metastatic genes (CCL2, APLN, IL6ST) was observed.
Conclusions:
- SEC-induced ANXA7 GTPase activation is a viable strategy to suppress prostate cancer metastasis, particularly in cases with low RKIP expression.
- The mechanism involves the AMPK/mTORC1/STAT3 signaling pathway.
- This study provides novel insights into targeting ANXA7 for prostate cancer therapy.
Related Concept Videos
The Ras Gene
Ras is a...
Cancer Cell Migration through Invadopodia
Abnormal Proliferation
GPCRs Regulate Adenylyl Cylase Activity
MAPK Signaling Cascades
Amplifying Signals via Enzymatic Cascade

